BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...to co-develop and co-commercialize oncolytic viruses from Transgene S.A....
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

SparingVision thinks its neuroprotective AAV therapy could benefit all retinitis pigmentosa patients, including those missed by mutation-targeted gene replacement therapies like Luxturna. The Paris-based...
BioCentury | Aug 13, 2020
Product Development

GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute

GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma.  GigaGen Inc. plans to submit an...
BioCentury | Aug 6, 2020
Finance

‘Not drip-feeding’: Andera looks to deploy record €450M fund to mostly European biotechs

Next year Andera aims to join the ranks of European life science VCs raising record funds with the close of its largest fund to date at €450 million. Andera Partners’ Olivier Litzka said the firm...
BioCentury | Aug 6, 2020
Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a transgenic mouse platform designed to generate...
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

...processes. “This is a platform where the delivery vehicle is not intimately tied to the transgene,”...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

...and SARS-CoV-2, and in vivo protection in Syrian golden hamsters, mice expressing a human ACE2 transgene...
BioCentury | Jun 11, 2020
Product Development

Emerging COVID-19 serology tests aim for neutralizing antibodies

The next wave of serology tests from big diagnostic players could get closer to telling people whether they are protected from COVID-19 by homing in on the antibodies most likely to block viral entry into...
BioCentury | Jun 2, 2020
Tools & Techniques

Spark’s approach to the problem of redosing AAV gene therapies

...pyogenes IdeS before delivery of a hemophilia AAV gene therapy raised gene transfer efficiency and transgene...
...Pretreatment with the enzyme lowered anti-AAV neutralizing antibody titers after the first infusion and boosted transgene...
BioCentury | Jun 1, 2020
Deals

Intellia deal expands Regeneron’s reach into CRISPR therapies

...to deliver the CRISPR machinery and an adeno-associated viral (AAV) vector to deliver a corrected transgene...
Items per page:
1 - 10 of 2417
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...to co-develop and co-commercialize oncolytic viruses from Transgene S.A....
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

SparingVision thinks its neuroprotective AAV therapy could benefit all retinitis pigmentosa patients, including those missed by mutation-targeted gene replacement therapies like Luxturna. The Paris-based...
BioCentury | Aug 13, 2020
Product Development

GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute

GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma.  GigaGen Inc. plans to submit an...
BioCentury | Aug 6, 2020
Finance

‘Not drip-feeding’: Andera looks to deploy record €450M fund to mostly European biotechs

Next year Andera aims to join the ranks of European life science VCs raising record funds with the close of its largest fund to date at €450 million. Andera Partners’ Olivier Litzka said the firm...
BioCentury | Aug 6, 2020
Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a transgenic mouse platform designed to generate...
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

...processes. “This is a platform where the delivery vehicle is not intimately tied to the transgene,”...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

...and SARS-CoV-2, and in vivo protection in Syrian golden hamsters, mice expressing a human ACE2 transgene...
BioCentury | Jun 11, 2020
Product Development

Emerging COVID-19 serology tests aim for neutralizing antibodies

The next wave of serology tests from big diagnostic players could get closer to telling people whether they are protected from COVID-19 by homing in on the antibodies most likely to block viral entry into...
BioCentury | Jun 2, 2020
Tools & Techniques

Spark’s approach to the problem of redosing AAV gene therapies

...pyogenes IdeS before delivery of a hemophilia AAV gene therapy raised gene transfer efficiency and transgene...
...Pretreatment with the enzyme lowered anti-AAV neutralizing antibody titers after the first infusion and boosted transgene...
BioCentury | Jun 1, 2020
Deals

Intellia deal expands Regeneron’s reach into CRISPR therapies

...to deliver the CRISPR machinery and an adeno-associated viral (AAV) vector to deliver a corrected transgene...
Items per page:
1 - 10 of 2417